Hong Kong Stock Exchange & Insilico Medicine
4 shared events · Importance 3 · Last updated Sep 10, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Hong Kong Stock Exchange: Exchange operator; methodology changes and index inclusion support its tech-focused product offerings.
Insilico Medicine: Central company; inclusion enhances visibility, liquidity, and capital access, likely benefiting its stock.
Jul 20, 2026 · 6 articles
Tech
Hong Kong Stock Exchange: The Hong Kong Stock Exchange is where Insilico Medicine is listed under stock code 3696, and the trial milestone may influence trading activity. The exchange itself is not directly affected.
Insilico Medicine: Insilico Medicine is the central actor, dosing the first patient in the Phase III trial of Rentosertib and reporting strong revenue growth and profitability. The milestone strengthens its AI-driven drug discovery narrative and could positively affect its Hong Kong-listed shares.
Sep 10, 2026 · 6 articles
Tech
Hong Kong Stock Exchange: Insilico Medicine is listed on the Hong Kong Stock Exchange, and this product launch may modestly affect its stock performance and the exchange's visibility in the biotech AI sector.
Insilico Medicine: Insilico Medicine is the developer and provider of the DDD Benchmark, leveraging its proprietary data and validated programs. This launch enhances its reputation as a leader in AI-driven drug discovery and could drive business growth through benchmarking services.
Jul 30, 2026 · 6 articles
Business
Hong Kong Stock Exchange: Listing venue for Tigermed's H-shares; results announced on its website.
Insilico Medicine: Signed strategic cooperation agreement with Tigermed, focusing on AI enablement in drug development.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Hong Kong Stock Exchange and Insilico Medicine interact across events, view sentiment trends, and discover connected entities.
Open Dashboard